Skip to Content

Generic Ultravate Availability

Ultravate is a brand name of halobetasol topical, approved by the FDA in the following formulation(s):

ULTRAVATE (halobetasol propionate - cream;topical)

  • Manufacturer: RANBAXY
    Approval date: December 27, 1990
    Strength(s): 0.05% [RLD] [AB]

ULTRAVATE (halobetasol propionate - lotion;topical)

  • Manufacturer: FERNDALE LABS INC
    Approval date: November 6, 2015
    Strength(s): 0.05% [RLD]

ULTRAVATE (halobetasol propionate - ointment;topical)

  • Manufacturer: RANBAXY
    Approval date: December 17, 1990
    Strength(s): 0.05% [RLD] [AB]

Has a generic version of Ultravate been approved?

A generic version of Ultravate has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ultravate and have been approved by the FDA:

halobetasol propionate cream;topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: December 16, 2004
    Strength(s): 0.05% [AB]
  • Manufacturer: G AND W LABS
    Approval date: April 24, 2007
    Strength(s): 0.05% [AB]
  • Manufacturer: PERRIGO ISRAEL
    Approval date: December 16, 2004
    Strength(s): 0.05% [AB]
  • Manufacturer: TARO
    Approval date: August 4, 2005
    Strength(s): 0.05% [AB]

halobetasol propionate ointment;topical

  • Manufacturer: G AND W LABS
    Approval date: September 7, 2006
    Strength(s): 0.05% [AB]
  • Manufacturer: PERRIGO
    Approval date: December 16, 2004
    Strength(s): 0.05% [AB]
  • Manufacturer: TARO
    Approval date: December 16, 2004
    Strength(s): 0.05% [AB]

Note: No generic formulation of the following product is available.

  • halobetasol propionate - lotion;topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultravate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Topical steroid composition and method
    Patent 8,962,028
    Issued: February 24, 2015
    Assignee(s): MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company
    Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.
    Patent expiration dates:
    • June 19, 2033
      ✓ 
      Patent use: USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide